Revision Applications for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research (U2C Clinical Trial Optional)

Research Group
Cancer Biomarkers
Expiration Date
Program Official
Guillermo Marquez, Ph.D.
Type of Funding Opportunity
RFA
Clinical Trials Status
Clinical Trial Optional
Announcement Number And URL
RFA-CA-23-011